Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wolff

Showing results (891-900 of 973) with videos related to

Pageof 98
Sort By:
Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?Awalpreet S Chadha, Guan Liu, Hsiang-Chun Chen, et al.
Oncotarget|December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patientsYehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
Annals of Surgical Oncology|August 17, 2019
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II TrialAlice C Wei, Fang-Shu Ou, Qian Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal CancerChristine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 3, 2006
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancerSunil Krishnan, Nora A Janjan, John M Skibber, et al.
The Lancet. Oncology|July 20, 2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trialClaus Rödel, Ullrich Graeven, Rainer Fietkau, et al.
Hepatology (Baltimore, Md.)|September 15, 2020
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma RiskJeffrey S Morris, Manal M Hassan, Ye Emma Zohner, et al.
Plos One|June 24, 2016
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic CancerAwalpreet S Chadha, Heath D Skinner, Jillian R Gunther, et al.
Journal of the National Cancer Institute|May 13, 2014
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinomaAhmed O Kaseb, Lianchun Xiao, Manal M Hassan, et al.
Pageof 98

Showing results (891-900 of 973) with videos related to

Sort By:
Pageof 98
Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?Awalpreet S Chadha, Guan Liu, Hsiang-Chun Chen, et al.
Oncotarget|December 6, 2022
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patientsYehia I Mohamed, Dan G Duda, Muhammad O Awiwi, et al.
Annals of Surgical Oncology|August 17, 2019
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II TrialAlice C Wei, Fang-Shu Ou, Qian Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal CancerChristine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 3, 2006
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancerSunil Krishnan, Nora A Janjan, John M Skibber, et al.
The Lancet. Oncology|July 20, 2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trialClaus Rödel, Ullrich Graeven, Rainer Fietkau, et al.
Hepatology (Baltimore, Md.)|September 15, 2020
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma RiskJeffrey S Morris, Manal M Hassan, Ye Emma Zohner, et al.
Plos One|June 24, 2016
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic CancerAwalpreet S Chadha, Heath D Skinner, Jillian R Gunther, et al.
Journal of the National Cancer Institute|May 13, 2014
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinomaAhmed O Kaseb, Lianchun Xiao, Manal M Hassan, et al.
Pageof 98